ETX2514

DRUG3 trials

Sponsors

Entasis Therapeutics

Conditions

Acinetobacter Baumannii InfectionAcinetobacter Baumannii-calcoaceticus Complex Infections

Phase 1

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

CompletedNCT02971423

Entasis TherapeuticsAcinetobacter Baumannii Infection

Start: 2016-10-31End: 2017-06-01Updated: 2017-06-05

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

CompletedNCT03985410

Entasis TherapeuticsAcinetobacter Baumannii-calcoaceticus Complex Infections

Start: 2019-05-23End: 2019-07-24Updated: 2019-08-30

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

CompletedNCT04018950

Entasis TherapeuticsAcinetobacter Baumannii-calcoaceticus Complex Infections

Start: 2019-06-21End: 2019-07-26Updated: 2019-08-30

Related Papers

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.

2020-06-2324 citations